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SHORT COMMUNICATION
Influence of delay in diagnosis on prognosis in testicular teratoma
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Testicular cancer incidence increased by 29% between 1968-
72 and 1978-82 in England and Wales. The cumulative
incidence from age 15 to 49 in 1978-82 was 206.1 per
100,000 compared to 160.1 per 100,000 in 1968-72 (Pike et
al., 1987). Two studies have suggested that there is
considerable ignorance among the general public as to the
signs of testicular tumours and the age group most at risk
(Thornhill et al., 1986; Cummings et al., 1983). Substantial
delays before seeking medical advice have been reported
(Jones & Appleyard, 1985; Oliver, 1985). Although some
authors have demonstrated a relationship between delay in
diagnosis and poor prognosis or outcome (Thornhill et al.,
1987; Oliver, 1985; Scher et al., 1983; Bosl et al., 1981),
others have found no evidence of such a relationship (Fossa
et al., 1981; Host & Stokke, 1959; Dixon & Moore, 1953).
We have investigated these findings further using data from
the Royal Marsden Hospital Testicular Tumour Unit.
Patients diagnosed to have testicular teratoma between 1
January 1980 and 31 December 1986 are included in this
analysis. Patients treated before their orchidectomy or at
hospitals other than the Royal Marsden are excluded, as are
those who did not have an orchidectomy, were not staged or
did not have serum marker levels determined before
chemotherapy. Information abstracted from case-notes
included duration of symptoms before orchidectomy.
Two hundred and fifty-seven patients fulfilling these
criteria were included in the analysis. The Royal Marsden
Hospital staging classification (Peckham et al., 1979) was
employed, and tumour volume designated as 'small' (stages I
(marker-positive), IIA, IIB, IIIA, IIIB, IVLI, IVL2), 'large'
(IIC, IIIC, IVCLI, IVCL2) or 'very large' (IVL3, IVH+,
IV Bone, IV Brain) as in the analysis carried out by the
MRC Working Party on Testicular Tumours (1985). High
and low markers and prognostic groups were also defined as
in that analysis. The maximum period of delay between
onset of symptoms and orchidectomy was 3 years with a
median delay of 2.5 months (mean 3.9 months). Durations
of delay were divided into three groups (0-49 days, 50-99
days and 100 days or more) with approximately equal
numbers of patients in each group. Analysis of relapse-free
survival excluding stage I marker-negative patients gave
results similar to those reported by the MRC Working Party
(1985). Prognostic group, as defined above, and marker
status were found to be significant determinants of relapse-
free survival (each had P<0.005). Relapse-free survival was
related to tumour volume but the trend did not reach
conventional statistical significance (log rank test for trend
x2=2.79, d.f.=1, P=0.09). Table I shows the relationship
between duration of delay and four prognostic factors: stage,
serum marker levels, tumour volume and prognostic group
(MRC, 1985).
There was little difference in prognostic factors at
presentation between men who delayed for 50-99 days and
those who sought help within 50 days. These two groups
have therefore been combined when carrying out statistical
tests. Of those who sought medical advice within 100 days of
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onset of symptoms, 54% had stage I tumours compared to
41% who delayed longer (2 =3.79, d.f. = 1, P=0.05). There
was no difference in tumour marker levels between those
who delayed for 100 or more days and those in the shorter
delay groups. The proportion of large and very large
tumours was much higher in those who delayed longest
(17% against 8%). Prognostic group did not show a
consistent relationship with delay, but of the men who had
delayed for 100 days or more 13% had very large tumours
with high marker levels (MRC group 6) compared to 3% of
those seeking help more promptly. Analysis of relapse-free
survival was undertaken separately for patients with
metastatic disease and those with stage I mnarker-negative
tumours because the latter group of patients enter our
surveillance programme and thus are treated quite differently
from those with metastatic disease. To our surprise, analysis
of relapse-free survival after chemotherapy in patients with
metastatic disease showed an inverse relationship between
delay and survival (Figure 1; log rank test for trend
x2=4.39, d.f.=1, P<0.05). Delay was unrelated to relapse-
free survival in stage I marker-negative tumours (Figure 2;
log rank test for trend x2=0.55, d.f.=1, P>0.1).
There are a number of components of delay (Jones &
Appleyard, 1985; Oliver, 1985): the total period between
onset of symptoms and orchidectomy is that considered here.
In our study the median delay between onset of symptoms
and orchidectomy was 2.5 months, similar to that reported
by Bosl et al. (1981) and Scher et al. (1983) in the USA.
Fossa et al. (1981) from Norway report a median in the
range 2-6 months. Jones & Appleyard (1985) in their UK
study report a median delay before consulting a doctor of 5
weeks, so the median delay before diagnosis is likely to be
similar to ours. Thornhill et al. (1987) in Ireland report 2.8
months' median delay before seeking medical advice so that
their delay to diagnosis is in excess of ours. From Oliver's
(1985) UK series a median delay of close to 6 months (24/52
patients delayed over 6 months) may be inferred. Host &
Stokke (1959) in Norway report only a mean delay (7.7
months) which is double our mean delay of 3.9 months.
Thus the recent studies are consistent in reporting median
delays of just over 2 months, with the exception of Oliver
(1985); there does not appear to be much variation between
different countries.
In terms of stage of disease neither Dixon & Moore (1953)
nor Fossa et al. (1981) found any evidence of an adverse
effect of delay, but Bosl et al. (1981) and Thornhill et al.
(1987) both found, as we have, that those with earlier stage
tumours had sought medical advice sooner than those with
late stage tumours. Possible explanations for the lack of
relationship between prognostic grouping and delay have
been put forward. Dixon & Moore (1953) suggested that
tumours destined to metastasise do so early and Fossa et al.
(1981) that the degree of aggressiveness of the clinical disease
far outweighed the importance of delay. Host & Stokke
(1959) considered that in the most malignant tumours,
symptoms would be so severe that an early consultation
would be likely. It is certainly feasible that slow growing
tumours would be less likely to be noticed or to cause
anxiety than faster growing tumours.
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Table I Prognostic factors by delay group
Delay (days)
Prognostic factor
Stage
I
II
III and IV
Total
Markers'
Lowa
Higha
Total
Tumour volumea
Stage 1 marker-negative
Small
Large
Very large
Total
Prognostic groupa
Stage I marker-negative
1-2
MRC 3-5
6
Total
0-49
45 (54%)
17 (20%)
22 (26%)
84 (100%)
25 (60%)
17 (40%)
42 (100%)
42 (50%)
29 (35%)
7 (8%)
6 (7%)
84 (100%)
42 (50%)
21 (25%)
19 (23%)
2 (2%)
84 (100%)
42 (55%)
15 (19%)
20 (26%)
77 (100%)
22 (61%)
14 (39%)
36 (100%)
41 (53%)
23 (30%)
8 (10%)
5 (6%)
77 (100%)
41 (53%)
20 (26%)
13 (17%)
3 (4%)
77 (100%)
39 (41%)
27 (28%)
30 (31%)
96 (100%)
32 (55%)
26 (45%)
58 (100%)
38 (40%)
26 (27%)
16 (17%)
16 (17%)
96 (100%)
38 (40%)
28 (29%)
18 (19%)
12 (13%)
96 (100%)
aSee text for definitions. bExcluding stage I marker-negative.
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Figure 1 Relapse-free survival from orchidectomy by delay
group, excluding stage I marker-negative patients. delay 0-
49 days, 42 cases (0=13, E=7.6); ---- delay 50-99 days, 36
cases (0=5, E=6.8); - - delay > 99 days, 58 cases (0=8,
E=11.6). Log rank test for trend: x2=4.39, d.f.=1, P<0.05.
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Figure 2 Relapse-free survival from orchidectomy by delay
group. Stage I marker-negative patients. delay 0-49 days,
42 cases (0=12, E=11.0); ---- delay 50-99 days, 41 cases
(0=12, E=10.5); - delay > 99 days, 38 cases (0=8,
E=10.5). Log rank test for trend: x2=0.55, d.f.=1, P>0.1.
Among the patients with advanced metastatic disease
studied by Scher et al. (1983), those who had delayed for
more than 3 months were less likely to respond to treatment
and were more likely to have palpable retroperitoneal
disease. Oliver (1985) and Thornhill et al. (1987) both found
that metastatic disease was more likely in those patients who
had delayed longer and Thornhill et al. (1987) also found a
significant inverse relationship between length of delay and
complete remission. More advanced disease was related to
delay in the MRC Working Party study (1985).
The findings with regard to survival are also inconsistent.
Fossa et al. (1981) found no relationship between survival
and delay but both Oliver (1985) and Thornhill et al. (1987)
found an adverse effect of delay on survival. The MRC
Working Party (1985) found no influence of delay on
survival once stage and marker status were taken into
account. In agreement with our findings, Host & Stokke
(1959) found their 'survival rate' to be worse in those with
the shortest period of delay.
Since we report an inverse relationship between delay and
relapse-free survival it seemed appropriate to investigate
whether delay might itelf be regarded as a prognostic factor.
Cox regression analysis (excluding stage I marker-negative
patients) indicated that, after allowing for prognostic group
(MRC, 1985), delay is a significant (P<0.05) prognostic
indicator of relapse. An alternative analysis of the prognostic
effect of delay after allowing for stage and marker levels
reached similar conclusions.
Although delay in seeking medical advice is in our data
inversely related to relapse the explanation that we propose
is that faster growing tumours are more likely to produce
symptoms leading to medical consultation. The
recommendation that early advice should be sought for any
observed testicular changes is not invalidated by this
observation. In the individual case the earliest possible
medical intervention is still the best hope of catching early
stage curable disease. Results of management of stage I
testicular tumours are excellent with a cure rate of more
than 95% (Freedman el al., 1987). Raising of public
awareness of this tumour by education programmes for both
the general public and the general practitioner must still be
the objective of health educators (Jones, 1987).
100 or
50-99 more All
126 (49%)
59 (23%)
72 (28%)
257 (100%)
79 (58%)
57 (42%)
136 (100%)
121 (47%)
78 (30%)
31 (12%)
27 (11%)
257 (100%)
121 (47%)
69 (27%)
50 (19%)
17 (7%)
257 (100%)
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